Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR

January 05, 2021

The combination of ibrutinib plus rituximab is approved for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL). In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined which advantages and disadvantages this drug combination has for the patients. For patients who could also be treated with the chemo-immunotherapy FCR, the assessment found an indication of a major added benefit in comparison with this appropriate comparator therapy. No study data are available for patients for whom FCR or other chemo-immunotherapy is not an option due to their poorer general health. An added benefit is therefore not proven.

Study data on only one of three research questions

The Federal Joint Committee (G-BA) distinguished three groups of patients. For the first group, which was also the largest, the appropriate comparator therapy was fludarabine + cyclophosphamide + rituximab (FCR). This chemo-immunotherapy is usually only given if the patient is in good general health. For the second group, FCR is not an option, but another chemo-immunotherapy is. In the third group, chemo-immunotherapies are generally not indicated, for example because of the mutation status of the patients. Here, the appropriate comparator therapy is ibrutinib alone.

In its dossier, the drug manufacturer only presented data on the question of whether ibrutinib plus rituximab offers an added benefit in comparison with FCR for the patients in the first group. These data are from the ongoing ECOG-E1912 study, which is not conducted by the manufacturer, but which it also used already in its application for approval. Data from about 40 per cent of the study participants are relevant for the present assessment.

Prolonged overall survival

There was an indication of a major added benefit for overall survival in patients for whom FCR therapy is an option. In the outcome category of side effects, there was a hint of lesser harm for the overall rate of severe side effects and for discontinuations due to side effects, which were of minor and of considerable extent respectively. Predominantly positive effects were shown in severe and non-serious/non-severe side effects. No results were available on health-related quality of life.

Overall, there is an indication of a major added benefit of ibrutinib plus rituximab in comparison with FCR for patients with previously untreated CLL for whom FCR therapy is an option. Since no data were available for the other patients, an added benefit in comparison with the respective appropriate comparator therapy is not proven for them.

Promising therapeutic option

"This means that a relatively large group of people with chronic lymphocytic leukaemia now have a chemotherapy-free treatment alternative that has a clear survival advantage," says Volker Vervölgyi from IQWiG's Drug Assessment Department. "This is good news, as we have not seen an added benefit in comparison with FCR in the previous early benefit assessments for untreated CLL."

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Health Articles from Brightsurf:

The mental health impact of pandemics for front line health care staff
New research shows the impact that pandemics have on the mental health of front-line health care staff.

Modifiable health risks linked to more than $730 billion in US health care costs
Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

New measure of social determinants of health may improve cardiovascular health assessment
The authors of this study developed a single risk score derived from multiple social determinants of health that predicts county-level cardiovascular disease mortality.

BU study: High deductible health plans are widening racial health gaps
The growing Black Lives Matter movement has brought more attention to the myriad structures that reinforce racial inequities, in everything from policing to hiring to maternal mortality.

Electronic health information exchange improves public health disease reporting
Disease tracking is an important area of focus for health departments in the midst of the COVID-19 pandemic.

E-health resource improves men's health behaviours with or without fitness facilities
Men who regularly used a free web resource made significantly more health changes than men who did not, finds a new study from the University of British Columbia and Intensions Consulting.

Mental health outcomes among health care workers during COVID-19 pandemic in Italy
Symptoms of posttraumatic stress disorder, depression, anxiety and insomnia among health care workers in Italy during the COVID-19 pandemic are reported in this observational study.

Mental health of health care workers in china in hospitals with patients with COVID-19
This survey study of almost 1,300 health care workers in China at 34 hospitals equipped with fever clinics or wards for patients with COVID-19 reports on their mental health outcomes, including symptoms of depression, anxiety, insomnia and distress.

Health records pin broad set of health risks on genetic premutation
Researchers from the University of Wisconsin-Madison and Marshfield Clinic have found that there may be a much broader health risk to carriers of the FMR1 premutation, with potentially dozens of clinical conditions that can be ascribed directly to carrying it.

Attitudes about health affect how older adults engage with negative health news
To get older adults to pay attention to important health information, preface it with the good news about their health.

Read More: Health News and Health Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.